ProQR Therapeutics (NASDAQ:PRQR) Upgraded to Sell by BidaskClub

BidaskClub upgraded shares of ProQR Therapeutics (NASDAQ:PRQR) from a strong sell rating to a sell rating in a research note issued to investors on Thursday, BidAskClub reports.

Other research analysts also recently issued research reports about the stock. ValuEngine raised shares of ProQR Therapeutics from a hold rating to a buy rating in a report on Wednesday, October 2nd. Zacks Investment Research raised shares of ProQR Therapeutics from a hold rating to a strong-buy rating and set a $10.00 target price for the company in a report on Wednesday, August 14th. Chardan Capital reaffirmed a buy rating and issued a $25.00 target price on shares of ProQR Therapeutics in a report on Friday, October 11th. Royal Bank of Canada reaffirmed a buy rating and issued a $27.00 target price on shares of ProQR Therapeutics in a report on Sunday, August 11th. Finally, Citigroup dropped their target price on shares of ProQR Therapeutics from $40.00 to $33.00 and set a buy rating for the company in a report on Tuesday. One analyst has rated the stock with a sell rating, six have given a buy rating and one has given a strong buy rating to the stock. ProQR Therapeutics presently has an average rating of Buy and an average price target of $25.83.

ProQR Therapeutics stock traded up $0.22 during mid-day trading on Thursday, hitting $8.40. The stock had a trading volume of 487,500 shares, compared to its average volume of 221,525. The firm has a market capitalization of $328.79 million, a P/E ratio of -6.51 and a beta of 0.24. The company has a current ratio of 7.01, a quick ratio of 7.01 and a debt-to-equity ratio of 0.18. The firm’s 50 day moving average is $6.85 and its 200 day moving average is $8.61. ProQR Therapeutics has a one year low of $5.49 and a one year high of $20.00.

Institutional investors have recently modified their holdings of the stock. Tower Research Capital LLC TRC purchased a new stake in ProQR Therapeutics in the 2nd quarter worth $79,000. Jane Street Group LLC purchased a new stake in ProQR Therapeutics in the 2nd quarter worth $92,000. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. lifted its stake in ProQR Therapeutics by 23.1% in the 2nd quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 10,535 shares of the biopharmaceutical company’s stock worth $96,000 after purchasing an additional 1,979 shares in the last quarter. Virtus ETF Advisers LLC lifted its stake in ProQR Therapeutics by 62.3% in the 2nd quarter. Virtus ETF Advisers LLC now owns 24,216 shares of the biopharmaceutical company’s stock worth $220,000 after purchasing an additional 9,291 shares in the last quarter. Finally, Northern Trust Corp lifted its stake in ProQR Therapeutics by 12.6% in the 2nd quarter. Northern Trust Corp now owns 38,742 shares of the biopharmaceutical company’s stock worth $353,000 after purchasing an additional 4,345 shares in the last quarter. 47.39% of the stock is owned by institutional investors.

ProQR Therapeutics Company Profile

ProQR Therapeutics N.V., a biopharmaceutical company, engages in the discovery and development of RNA-based therapeutics for the treatment of genetic disorders. Its lead product candidates include eluforsen, a RNA-based oligonucleotide used for the treatment of cystic fibrosis; QR-110, an oligonucleotide that is designed to treat Leber's congenital amaurosis; QR-313, a dermatology candidate for the treatment of epidermolysis bullosa; and QR-421a and QR-411 to treat type 2A Usher syndrome.

See Also: What is the Quick Ratio?

Analyst Recommendations for ProQR Therapeutics (NASDAQ:PRQR)

Receive News & Ratings for ProQR Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProQR Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.